Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors
Authors' conclusion
There is wide variability in the content of the published RA outcome descriptions, as well as a lack of descriptions regarding common patient-important outcomes.
Study context
- Population
- Published English-language descriptions of seven Rheumatoid Arthritis (RA) outcomes (selected by author consensus from a living systematic review of RA drug therapy) in patient-decision aids (PtDAs) and patient preference studies11 PtDAs and 27 preference studies
- Participants
- 11 vs 27
- Comparison
- PtDAs vs Preference studies
- PtDAsn = 11
- Preference studiesn = 27
- Outcome
- How RA outcomes have been described to patients, mapped to the HOD framework (Symptoms, Time horizon, Testing and Treatment, Consequences)
Methodological detailsthematic content analysis, narrative summary
- Thematic content analysis
- Narrative summary
Main finding
As reported in the abstract
Description of RA outcomes
- Adverse events (AEs) described
- N = 26/38
- Remission described: PtDAs
- N = 2/11
- Remission described: preference studies
- N = 1/27
- Pain described: PtDAs
- N = 2/11
- Pain described: preference studies
- N = 6/27
- Health Outcome Descriptor (HOD) domain: descriptions focused on symptoms
- 94 %
- HOD domain: other domains
- 18-38 %
Original publication
Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors. Semin Arthritis Rheum. Published 6 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →